Sodium lauryl sulfate
Identification
- Summary
Sodium lauryl sulfate is an anionic surfactant used in cosmetics and pharmaceuticals as a fat emulsifier, wetting agent, and detergent.
- Generic Name
- Sodium lauryl sulfate
- DrugBank Accession Number
- DB00815
- Background
Sodium Lauryl Sulfate (SLS) is an anionic surfactant naturally derived from coconut and/or palm kernel oil. It usually consists of a mixture of sodium alkyl sulfates, mainly the lauryl. SLS lowers surface tension of aqueous solutions and is used as fat emulsifier, wetting agent, and detergent in cosmetics, pharmaceuticals and toothpastes. It is also used in creams and pastes to properly disperse the ingredients and as research tool in protein biochemistry. SLS also has some microbicidal activity.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 288.379
Monoisotopic: 288.137124653 - Chemical Formula
- C12H25NaO4S
- Synonyms
- Laurylsiran sodny
- NaDS
- Natrium laurylsulfuricum
- SDS
- SLS
- Sodium dodecyl sulfate
- Sodium dodecyl sulphate
- Sodium dodecylsulfate
- Sodium laurilsulfate
- Sodium lauryl sulfate
- Sodium lauryl sulphate
- External IDs
- Caswell No. 779
- Rhodapon SB 8208S
Pharmacology
- Indication
SLS is used as a surfactant in shampoos and toothpastes. SLS also has microbicidal activities against both enveloped (Herpes simplex viruses, HIV-1, Semliki Forest virus) and nonenveloped (papillomaviruses, reovirus, rotavirus and poliovirus) viruses, although it has not been approved for this use.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
SLS is an anionic surfactant. Its amphiphilic properties make it an ideal detergent.
- Mechanism of action
Like other surfactants, SLS is amphiphilic. It thus migrates to the surface of liquids, where its alignment and aggregation with other SLS molecules lowers the surface tension. This allows for easier spreading and mixing of the liquid. SLS has potent protein denaturing activity and inhibits the infectivity of viruses by by solubilizing the viral envelope and/or by denaturing envelope and/or capsid proteins.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Oral (LD50): Acute: 1288 mg/kg [Rat]
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Take after a meal. When Sodium lauryl sulfate is formulated in paste form for oral health, it should be used after meals.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Active Moieties
Name Kind UNII CAS InChI Key Dodecyl sulfate unknown DIQ16UC154 151-41-7 MOTZDAYCYVMXPC-UHFFFAOYSA-N - International/Other Brands
- Anticerumen / Emal 10 / Empicol / Genapol LSS / Irium
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Bamboo Salt Paste, dentifrice 0.7675 g/100g Oral Hanul Trading Co., Ltd. 2015-03-19 2017-06-24 US Bamboo Salt 160g Paste, dentifrice 1.21 g/160g Oral Hanul Trading Co., Ltd. 2015-03-19 Not applicable US Dr.G Hydra Intensive Moist Cleansing gel Liquid 25 g/100mL Topical GOWOONSESANG COSMETICS CO., LTD. 2015-07-10 2018-01-19 US Sensible Paste 2 g/100g Dental Guardian Angel of Preventive Dentistry 2014-07-11 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image For Sope Sodium lauryl sulfate (97 %) + Stearic acid (1.5 %) Liquid Topical Rougier Pharma Division Of Ratiopharm Inc 1960-12-31 1999-09-27 Canada Medi Hydro DP Cleanser Sodium lauryl sulfate (0.15 g/100g) + Allantoin (0.005 g/100g) + Titanium dioxide (0.05 g/100g) Cream Topical Mbg Inc (Korea Institute of Science Development) 2016-08-15 2017-08-15 US Plax Anti-plaque Dental Rinse Sodium lauryl sulfate (0.25 %) + Sodium benzoate (2 %) + Sodium salicylate (0.2 %) Liquid Dental Johnson & Johnson 1988-12-31 2010-08-04 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dr.G Hydra Intensive Moist Cleansing gel Sodium lauryl sulfate (25 g/100mL) Liquid Topical GOWOONSESANG COSMETICS CO., LTD. 2015-07-10 2018-01-19 US Medi Hydro DP Cleanser Sodium lauryl sulfate (0.15 g/100g) + Allantoin (0.005 g/100g) + Titanium dioxide (0.05 g/100g) Cream Topical Mbg Inc (Korea Institute of Science Development) 2016-08-15 2017-08-15 US Trimo San Sodium lauryl sulfate (0.1 mg/1g) + Oxyquinoline sulfate (0.25 mg/1g) Jelly Vaginal CooperSurgical, Inc. 1977-04-01 Not applicable US Trimo-San Sodium lauryl sulfate (0.1 mg/1g) + Oxyquinoline sulfate (0.25 mg/1g) Jelly Vaginal Denison Pharmaceuticals, Llc 2019-09-16 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as sulfuric acid monoesters. These are organic compounds containing the sulfuric acid monoester functional group, with the generic structure ROS(O)(=O)=O, (R=organyl group).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic sulfuric acids and derivatives
- Sub Class
- Sulfuric acid esters
- Direct Parent
- Sulfuric acid monoesters
- Alternative Parents
- Alkyl sulfates / Organooxygen compounds / Organic sodium salts / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aliphatic acyclic compound / Alkyl sulfate / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic salt / Organic sodium salt / Organooxygen compound / Sulfate-ester
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- alkyl sulfate (CHEBI:8984)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 368GB5141J
- CAS number
- 151-21-3
- InChI Key
- DBMJMQXJHONAFJ-UHFFFAOYSA-M
- InChI
- InChI=1S/C12H26O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1
- IUPAC Name
- sodium dodecyl sulfate
- SMILES
- [Na+].CCCCCCCCCCCCOS([O-])(=O)=O
References
- Synthesis Reference
Willi Breitzke, Hermann Hensen, "Aqueous preparations of sodium lauryl sulfate and myristyl sulfate having a low cloud point useful in making toothpastes." U.S. Patent US4876035, issued June, 1960.
US4876035- General References
- Agner T: Susceptibility of atopic dermatitis patients to irritant dermatitis caused by sodium lauryl sulphate. Acta Derm Venereol. 1991;71(4):296-300. [Article]
- Marrakchi S, Maibach HI: Sodium lauryl sulfate-induced irritation in the human face: regional and age-related differences. Skin Pharmacol Physiol. 2006;19(3):177-80. Epub 2006 May 4. [Article]
- Loffler H, Effendy I: Skin susceptibility of atopic individuals. Contact Dermatitis. 1999 May;40(5):239-42. [Article]
- Chahine L, Sempson N, Wagoner C: The effect of sodium lauryl sulfate on recurrent aphthous ulcers: a clinical study. Compend Contin Educ Dent. 1997 Dec;18(12):1238-40. [Article]
- Herlofson BB, Barkvoll P: The effect of two toothpaste detergents on the frequency of recurrent aphthous ulcers. Acta Odontol Scand. 1996 Jun;54(3):150-3. [Article]
- Piret J, Desormeaux A, Bergeron MG: Sodium lauryl sulfate, a microbicide effective against enveloped and nonenveloped viruses. Curr Drug Targets. 2002 Feb;3(1):17-30. [Article]
- External Links
- MSDS
- Download (75.2 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Terminated Treatment Bacterial Vaginosis (BV) / Vaginal Discharge / Vaginosis 1 3 Completed Treatment Allergic Reaction 1 2, 3 Completed Prevention Bacterial Vaginosis (BV) 1 1 Completed Not Available Surgical Site Infections 1 1 Completed Basic Science Healthy Subjects (HS) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Amend
- Carrington
- Coopersurgical Inc.
- Nutricia
- Dosage Forms
Form Route Strength Paste, dentifrice Oral 0.7675 g/100g Paste, dentifrice Oral 1.21 g/160g Liquid Topical 25 g/100mL Liquid Topical Gel Gel 45 MG Cream Topical Liquid Dental Paste Dental 2 g/100g Jelly Vaginal - Prices
Unit description Cost Unit Monogen powder 0.09USD g Sodium lauryl sulfate cryst 0.03USD g Carrington whirlpool solution 0.01USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 205.5 °C PhysProp water solubility 1E+005 mg/L SINGER,MM & TJEERDEMA,RS (1993) logP 1.60 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.0121 mg/mL ALOGPS logP 3.86 ALOGPS logP 4.42 Chemaxon logS -4.4 ALOGPS pKa (Strongest Acidic) -1.5 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 66.43 Å2 Chemaxon Rotatable Bond Count 12 Chemaxon Refractivity 67.81 m3·mol-1 Chemaxon Polarizability 31.17 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9391 Blood Brain Barrier + 0.9611 Caco-2 permeable - 0.6041 P-glycoprotein substrate Non-substrate 0.7529 P-glycoprotein inhibitor I Non-inhibitor 0.73 P-glycoprotein inhibitor II Non-inhibitor 0.9563 Renal organic cation transporter Non-inhibitor 0.9123 CYP450 2C9 substrate Non-substrate 0.8755 CYP450 2D6 substrate Non-substrate 0.8532 CYP450 3A4 substrate Non-substrate 0.5576 CYP450 1A2 substrate Non-inhibitor 0.7976 CYP450 2C9 inhibitor Non-inhibitor 0.8219 CYP450 2D6 inhibitor Non-inhibitor 0.8946 CYP450 2C19 inhibitor Non-inhibitor 0.7743 CYP450 3A4 inhibitor Non-inhibitor 0.9845 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8892 Ames test Non AMES toxic 0.6075 Carcinogenicity Carcinogens 0.7009 Biodegradation Ready biodegradable 0.9703 Rat acute toxicity 2.3453 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5379 hERG inhibition (predictor II) Non-inhibitor 0.7424
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-070g-7930000000-112a35183d2ba1b6ef5c MS/MS Spectrum - Quattro_QQQ 10V, Positive LC-MS/MS splash10-000i-0090000000-12b55f58de196159b535 MS/MS Spectrum - Quattro_QQQ 25V, Positive LC-MS/MS splash10-00di-9000000000-55a0d8975342d4745eee MS/MS Spectrum - Quattro_QQQ 40V, Positive LC-MS/MS splash10-00di-9000000000-55a0d8975342d4745eee 1H NMR Spectrum 1D NMR Not Applicable 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 161.54259 predictedDeepCCS 1.0 (2019) [M+H]+ 165.56267 predictedDeepCCS 1.0 (2019) [M+Na]+ 174.82489 predictedDeepCCS 1.0 (2019)
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Binder
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Chang-Ying Y, An-Xin H, Yi L, Hui T, Song-Sheng Q: Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7. [Article]
- Choi EJ, Foster MD: Surfactant displacement of human serum albumin adsorbed on loosely packed self-assembled monolayers: cetyltrimethylammonium bromide versus sodium dodecyl sulfate. J Colloid Interface Sci. 2003 May 15;261(2):273-82. [Article]
- Santos SF, Zanette D, Fischer H, Itri R: A systematic study of bovine serum albumin (BSA) and sodium dodecyl sulfate (SDS) interactions by surface tension and small angle X-ray scattering. J Colloid Interface Sci. 2003 Jun 15;262(2):400-8. [Article]
- Cao WG, Jiao QC, Liu Q: [Spatial orientation interaction mechanism of three component complex of protein--BSA/SDS/Azur a system]. Guang Pu Xue Yu Guang Pu Fen Xi. 2005 Sep;25(9):1478-81. [Article]
- Schweitzer B, Felippe AC, Dal Bo A, Minatti E, Zanette D, Lopes A: Sodium dodecyl sulfate promoting a cooperative association process of sodium cholate with bovine serum albumin. J Colloid Interface Sci. 2006 Jun 1;298(1):457-66. Epub 2006 Feb 2. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 02, 2024 22:44